Flagship Pioneering Launches Flagship Origination Lab in London to Create AI-Native Platform Companies in the U.K.

Detailed summary
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced the establishment of Flagship Origination Lab, U.K., its first dedicated company creation unit outside of the U.S. Based in London, the Lab will conceive, test, fund, and build AI-native platform companies that advance human and planetary health and other frontiers of science and technology.
Flagship commits an initial £100 million to launch and build the new company origination capability
First expansion of Flagship Labs' company-creation model beyond Cambridge, Massachusetts
CAMBRIDGE, Mass. & LONDON, Nov. 16, 2026 /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced the establishment of Flagship Origination Lab, U.K., its first dedicated company creation unit outside of the U.S. Based in London, the Lab will conceive, test, fund, and build AI-native platform companies that advance human and planetary health and other frontiers of science and technology. Flagship has committed an initial £100 million to launch the Lab, which will operate as part of Flagship Labs, the company's innovation foundry.
For more than 25 years, Flagship has employed its unique model of pursuing bold scientific questions, developing breakthrough innovations, originating transformative platforms and products, and creating more than 130 companies to date, including Moderna. That legacy has created a deep and compounding base of scientific insight, company-building expertise, infrastructure, capital, and global relationships – strengthening Flagship's ability to pursue increasingly ambitious opportunities at the intersection of life sciences, AI, and beyond.
Flagship's Origination Lab, U.K. will build on three years of experience partnering and conducting R&D across the U.K. Since opening an office in London and signing an MOU with the U.K. Government in 2023 to extend the global reach and impact of its companies, Flagship has launched its first transatlantic company, Quotient Therapeutics; accelerated first-in-category clinical trials across the U.K. by Flagship-founded companies such as Generate:Biomedicines; and developed numerous strategic partnerships across academia, data, and regulatory innovation.
"Today marks the beginning of a new chapter in Flagship's relationship with the U.K.," said Noubar Afeyan…
Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)




